REFLECTIONBIO®

Currently, there is no approved treatment for BCD. ReflectionBio® is developing gene therapy for BCD. BCD gene therapy has shown promising results in preclinical study. We are advancing BCD gene therapy R&D into human clinical trial... ReflectionBio® is a unique, rare disease patient-driven biotechnology company. There are about 8,000 rare diseases, more than 90% of which do not have any approved treatment available. Among 200+ genes whose mutations can cause blindness, only one gene therapy has been developed and approved by the FDA... Reflection Biotechnologies (ReflectionBio®) focuses on rare, genetic diseases and other challenging diseases which currently have no or few treatment options available. Rare disease patients shoulder the inevitable odds of genetic mutations for mankind, but are often ignored by society and under-supported by public resources. At ReflectionBio®, we aim to develop life-changing, long-lasting and breakthrough gene therapies for patients suffering from..